According to Mayne Pharma Group latest financial reports the cash on hand of MYX is $137.18M, an increase of 127.72% to 2022. At the end of 2022 company had $60.24M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $137.18M | 127.72% |
2022 | $60.24M | -1.33% |
2021 | $61.06M | -28.89% |
2020 | $85.86M | 54.81% |
2019 | $55.46M | - |